Navigation Links
Spherix Announces Second Quarter 2010 Financial Results
Date:8/17/2010

American Society of Pharmacognosy, Phytochemical Society of North America, July 10-14, 2010, St. Petersburg Beach, FL
  • 2010 IFT Annual Meeting & Food Expo, July 12-20, 2010, Chicago, IL
  • Rodman and Renshaw Global Investment Conference, Sept. 12-15, New York, NY

    • Financial Results for the Quarter Ended June 30, 2010Revenue and direct costs are directly related to the Company's health sciences consulting segment.  The Company's consulting business provides technical and regulatory consulting services to biotechnology and pharmaceutical companies, as well as critical technical support for the Company's own R&D activities.

    The Company's ongoing research and development activities have been focused on the development of D-tagatose as a new treatment for Type 2 diabetes.  The Company announced in June that it would also explore D-Tagatose as a potential treatment for high triglycerides, a risk factor for atherosclerosis, myocardial infraction, and stroke. The R&D expenditures for 2010 and 2009 consisted of both a Phase 3 clinical trial and a related Phase 2 Dose Range study on the use of D-tagatose as a treatment for Type 2 diabetes.  The increase in R&D costs for the three-month period ended June 30, 2010 over the same period in 2009 is related to the close-out procedures the Company is performing for the Phase 3 trial.

    D-Tagatose is believed to depress elevations of blood sugar levels in diabetic patients by increasing glycogen synthesis while decreasing glycogen utilization, resulting in an improvement of blood sugar control and modulation of HbA1c. The Phase 3 efficacy trial results are expected to be unblinded in mid-September and the Dose Range study is expected to be completed by the end of 2010.

    The increase in selling, general and administrative costs between 2010 and 2009 is primarily related to the expansion of the Company's market development efforts of D-tagatose as a tr
    '/>"/>

    SOURCE Spherix Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
    2. Spherix Transfers Stock Listing to Nasdaq Capital Market
    3. Spherix Reports 3rd Quarter Earnings
    4. Spherix Announces 2008 Financial Results
    5. Spherix Recruiting New Independent Director to Regain NASDAQ Compliance
    6. Spherix Incorporated Announces the Death of A. Paul Cox, Jr., Chairman of the Board
    7. Spherix to Exhibit at the BIO 2009 International Convention
    8. Spherix Regains Full NASDAQ Compliance
    9. Spherix Announces Full-Scale Production of Pharmaceutical Tagatose
    10. Spherix Announces Termination of Arla License Agreement
    11. Spherix Reports Second Quarter 2009 Earnings
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/23/2013)... MD (PRWEB) May 23, 2013 Can ... off from work motivate members of the public to ... researchers including Johns Hopkins Carey Business School ... emphatic yes. Pointing to a large body of recent ... in the May 24, 2013, issue of Science that ...
    (Date:5/23/2013)... SCHOFIELD, Wis. , May 23, 2013 /PRNewswire/ ... a researcher, developer, and marketer of over-the-counter (OTC) ... re-issued its research opinion on the company based ... Highlights , Non-Prescription, All Natural Product ... Show the Product Outperforms #1 Prescription Competitor ...
    (Date:5/23/2013)... 2013 PI’s new LPS-24 positioners ... 15 mm travel range with closed-loop sensor resolution ... make these new positioners the ideal choice for ... rated version is also available. , More ... can be found at: , http://www.physikinstrumente.com/en/products/prdetail.php?sortnr=1000745&prw-lps24 ...
    (Date:5/23/2013)... , May 23, 2013 Virobay, Inc. ... for pain has reached an important milestone, as Virobay ... VBY-036 - a selective cathepsin S inhibitor.   ... a double-blind, randomized, placebo-controlled study designed to evaluate the ... VBY-036 in healthy adults. "The initiation of ...
    Breaking Biology Technology:Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3
    ... Inc., a privately held company leading the development of ... J. Mazzo, PhD, President and CEO, will be presenting ... 10 a.m. EDT on April 4, 2012 at the ... The presentation will include an overview of the ...
    ... ever smaller and more powerful computer chips are in ... that accelerates this progress. Prof. Dr. Padma Kant Shukla ... in quantum plasmas. A negatively charged potential makes it ... structures within the plasma. In this way, current can ...
    ... aura of magic about it because it suddenly reveals what ... So, too, with photoacoustic tomography, which is allowing scientists to ... see what lies beneath. The technique achieves this depth ... the high contrast due to light absorption by colored molecules ...
    Cached Biology Technology:Regado Biosciences, Inc. to Present at Needham & Company's 11th Annual Healthcare Conference in New York, NY 2Regado Biosciences, Inc. to Present at Needham & Company's 11th Annual Healthcare Conference in New York, NY 3When ions get closer 2New imaging technique moves from lab to clinic 2New imaging technique moves from lab to clinic 3New imaging technique moves from lab to clinic 4New imaging technique moves from lab to clinic 5
    (Date:5/24/2013)... 500 leading water scientists from around the world today ... the short span of one or two generations, the ... be living under the handicap of severe pressure on ... there is no substitute. This handicap will be self-inflicted ... bluntly pointed to chronic underlying problems led by mismanagement ...
    (Date:5/23/2013)... at Emory University, along with partners at the ... million grant over four years to establish the ... Research Center: Understanding Lifetime Exposures). The grant is ... United States. , The HERCULES Center is ... Sciences (NIEHS) of the National Institutes of Health ...
    (Date:5/23/2013)... A new report from the Institute of Medicine ... in at least 60 minutes of vigorous or moderate ... than half of American youth meet current evidence-based guidelines ... intensity physical activity daily, according to the report, which ... school for nearly half of their waking hours, the ...
    Breaking Biology News(10 mins):A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 2A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 3A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 4Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Schools should provide students with daily physical activity, IOM recommends 2
    ... published today in Nature Genetics shows that some rearrangements ... thought. The work is likely to lead to new ... diagnosis of genomic disease. The scientists from the ... in the genome where rearrangements cause genetic diseases, so-called ...
    ... whose skulls were made whole again by bone tissue ... Healing critical-size defects (defects that would not otherwise heal ... type that forms the skull, is a vivid demonstration ... University to use hESCs for tissue regeneration. ...
    ... Individuals with either current or past insomnia are more ... those who have never had the sleep disorder, according to ... journal SLEEP. The study, authored by Simon Beaulieu-Bonneau, MPs, ... Canada, focused on 953 adults between 18 and 83 years ...
    Cached Biology News:Mutant sperm guide clinicians to new diseases 2Mutant sperm guide clinicians to new diseases 3Human embryonic stem cell -- derived bone tissue closes massive skull injury 2Journal Sleep: Insomniacs are more likely to report a family history of the sleep disorder 2
    ... ligase (AMP forming), Acetate thiokinase ... Physical form: Lyophilized powder containing ... glutathione Preparation Unit Definition: One ... coenzyme A from acetate, ATP and coenzyme ...
    ... This CLS number is a ... match Cornings product number. If showing ... the old Sigma-Aldrich number (Z71,487-9) or ... ID clarifier: centre neck 100 mm, ...
    ... Blasticidin is a nucleoside ... It is a potent ... prokaryotic and eukaryotic cells. ... conferred by the products ...
    ... (Aph-1aL,S Loop 92-115), O2F1 Affinity Purified ... multiprotein complex consisting of presenilin, nicastrin, ... are necessary for full proteolytic activity. ... of a number of integral membrane ...
    Biology Products: